MUNDIBIOPHARMA LIMITED

09273949
Active Cambridge

Wholesale of pharmaceutical goods

8 employees website.com
Life sciences and medical technology Wholesale of pharmaceutical goods
M

MUNDIBIOPHARMA LIMITED

09273949

Wholesale of pharmaceutical goods

Founded 21 Oct 2014 Active Cambridge, England 8 employees website.com
Life sciences and medical technology Wholesale of pharmaceutical goods
Accounts Submitted 9 Sept 2025 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 29 Jun 2026 Next due 27 Jun 2027 11 months remaining
Net assets £93M £7M 2023 year on year
Total assets £231M £15M 2023 year on year
Total Liabilities £138M £22M 2023 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Unit 191 Cambridge Science Park Milton Road Cambridge CB4 0GW England

Telephone

0800 000 0000

Website

www.example.com

Full company profile for MUNDIBIOPHARMA LIMITED (09273949), an active life sciences and medical technology company based in Cambridge, England. Incorporated 21 Oct 2014. Wholesale of pharmaceutical goods. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 2 months remaining

Balance Sheet & P&L (2015–2023)

Cash in Bank

£45.83M

Increased by £28.48M (+164%)

Net Assets

£93.23M

Increased by £6.72M (+8%)

Total Liabilities

£137.87M

Decreased by £22.10M (-14%)

Turnover

£206.15M

Decreased by £32.06M (-13%)

Employees

8

Increased by 2 (+33%)

Debt Ratio

60%

Decreased by 5 (-8%)

Financial History

Revenue, profit, EBITDA and key financial figures

2023
31 Dec Year End
2022
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

3 Allotments 692 Shares £69.20m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
15 Dec 2016160€16.00m€100k
11 Jan 2016171€17.10m€100k
10 Dec 2015361€36.10m€100k

Officers

Officers

1 active 2 resigned
Status
Jamieson, Stephen JohanDirectorBritishUnited Arab Emirates6822 Feb 2019Active

Shareholders

Shareholders (3)

Purdue Biopharma L.p
99.8%
805
Cedar Rock Investment Corporation
0.1%
1

Persons with Significant Control

Persons with Significant Control (6)

6 Active 3 Ceased

Stephen Schreiner

American

Active
Notified 31 Dec 2019
Residence United States
DOB May 1959
Nature of Control
  • Significant Influence Or Control As Trust

Jared Giddens

American

Active
Notified 31 Dec 2019
Residence United States
DOB November 1956
Nature of Control
  • Significant Influence Or Control As Trust

Alexa Mairi Saunders

British

Active
Notified 5 Mar 2018
Residence Jersey
DOB September 1978
Nature of Control
  • Significant Influence Or Control As Trust

Richard Stephen Sackler

American

Active
Notified 6 Apr 2016
Residence United States
DOB March 1945
Nature of Control
  • Ownership Of Shares 25 To 50 Percent As Trust

Dr Richard Stephen Sackler

American

Active
Notified 6 Apr 2016
Residence United States
DOB March 1945
Nature of Control
  • Ownership Of Shares 25 To 50 Percent As Trust

Hermance Bernadette Monique Schaepman

French

Active
Notified 6 Apr 2016
Residence France
DOB November 1953
Nature of Control
  • Ownership Of Shares 25 To 50 Percent As Trust

Jonathan David Sackler

Ceased 30 Jun 2020

Ceased

Peter Minton Ward

Ceased 3 Jun 2018

Ceased

Christopher Benbow Mitchell

Ceased 12 Apr 2018

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
29 Jun 2026Confirmation StatementConfirmation statement made on 13 Jun 2026 with updates
17 Mar 2026CapitalCapital Alter Shares Redemption Statement Of Capital
17 Nov 2025OfficersChange to director Mr Stephen Johan Jamieson on 5 Nov 2025
9 Sept 2025AccountsAnnual accounts made up to 31 Dec 2024
13 Jun 2025Confirmation StatementConfirmation statement made on 13 Jun 2025 with no updates
29 Jun 2026 Confirmation Statement

Confirmation statement made on 13 Jun 2026 with updates

17 Mar 2026 Capital

Capital Alter Shares Redemption Statement Of Capital

17 Nov 2025 Officers

Change to director Mr Stephen Johan Jamieson on 5 Nov 2025

9 Sept 2025 Accounts

Annual accounts made up to 31 Dec 2024

13 Jun 2025 Confirmation Statement

Confirmation statement made on 13 Jun 2025 with no updates

Recent Activity

Latest Activity

Confirmation statement made on 13 Jun 2026 with updates

4 days ago on 29 Jun 2026

Capital Alter Shares Redemption Statement Of Capital

3 months ago on 17 Mar 2026

Change to director Mr Stephen Johan Jamieson on 5 Nov 2025

7 months ago on 17 Nov 2025

Annual accounts made up to 31 Dec 2024

9 months ago on 9 Sept 2025

Confirmation statement made on 13 Jun 2025 with no updates

1 years ago on 13 Jun 2025